CureVac N.V. (CVAC)

USD 2.75

(-6.78%)

Market Cap (In USD)

616.84 Million

Revenue (In USD)

53.75 Million

Net Income (In USD)

-260.16 Million

Avg. Volume

755.45 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.215-5.28
PE
-
EPS
-
Beta Value
2.611
ISIN
NL0015436031
CUSIP
N2451R105
CIK
1809122
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alexander Zehnder M.B.A., M.D.
Employee Count
-
Website
https://www.curevac.com
Ipo Date
2020-08-14
Details
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.